104173-41-3

Basic information

• Product Name: 1-[3-(trifluoromethyl)phenyl]cyclopropane-1-carboxylic acid
• Synonyms: 1-[3-(trifluoromethyl)phenyl]cyclopropane-1-carboxylic acid
• CAS NO: 104173-41-3
• Molecular Formula: C₁₁H₉F₃O₂
• Molecular Weight: 230.184
• Mol File: 104173-41-3.mol

Chemical Properties

• Boiling Point: 285.8°C at 760 mmHg
• Flash Point: 126.6°C
• Appearance: /
• Density: 1.424g/cm³
• Vapor Pressure: 0.00128mmHg at 25°C
• Refractive Index: 1.521
• CAS DataBase Reference: 1-[3-(trifluoromethyl)phenyl]cyclopropane-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[3-(trifluoromethyl)phenyl]cyclopropane-1-carboxylic acid(104173-41-3)
• EPA Substance Registry System: 1-[3-(trifluoromethyl)phenyl]cyclopropane-1-carboxylic acid(104173-41-3)

Safety Data

• Hazardous Substances Data: 104173-41-3(Hazardous Substances Data)

Usage

Structure

Cyclopropane carboxylic acid derivative with a trifluoromethylphenyl group

Potential applications

Building block in the synthesis of pharmaceuticals and agrochemicals

Unique properties

Exhibits unique structure and reactivity due to the presence of cyclopropane and trifluoromethyl moieties

Research interest

Interesting target for chemical research and development

Carboxylic acid group

Suggests potential applications in medicinal chemistry as a potential drug candidate

InChI:InChI=1/C11H9F3O2/c12-11(13,14)8-3-1-2-7(6-8)10(4-5-10)9(15)16/h1-3,6H,4-5H2,(H,15,16)

Upstream product

• 2338-76-3 3-trifluoromethylphenylacetonitrile 
• 104173-37-7 2,2-Dibromo-1-(3-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester 
• 104173-36-6 2-<3-(Trifluormethyl)phenyl>acrylsaeure-ethylester 
• 331-33-9 ethyl 3-trifluoromethylphenylacetate 
• 104173-39-9 1-(3-Trifluoromethyl-phenyl)-cyclopropanecarboxylic acid methyl ester 

Downstream Products

• 1309358-74-4 N-[2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethyl)phenyl]-1-[3-(trifluoromethyl)-phenyl]cyclopropanecarboxamide 
• 1252638-56-4 (4R)-4-{[2-chloro-4-(2,2,2-trifluoroethoxy)phenyl]sulfonyl}-N-(1-cyanocyclopropyl)-1-({1-[3-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)-L-prolinamide 
• 1252641-15-8 (4R)-4-[(2-chlorophenyl)sulfonyl]-N-(1-cyanocyclopropyl)-1-({1-[3-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)-L-prolinamide 
• 501698-49-3 1-[3-(trifluoromethyl)-phenyl]cyclopropanecarbonyl chloride 

Relevant articles and documents

Rhodium-Catalyzed Enantioselective Silylation of Cyclopropyl C?H Bonds

Hydrosilyl ethers, generated in situ by the dehydrogenative silylation of cyclopropylmethanols with diethylsilane, undergo asymmetric, intramolecular silylation of cyclopropyl C?H bonds in high yields and with high enantiomeric excesses in the presence of

Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8- (trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury

Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure-activity studies in this series by branching at the α position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.

Methods and Compositions for Selectin Inhibition

The present teachings relate to novel compounds of formula I: wherein the constituent variables are as defined herein. Compounds of the present teachings can act as antagonists of the mammalian adhesion proteins known as selecting. Methods for treating or preventing selectin-mediated disorders are provided, which include administration of these compounds in a therapeutically effective amount.

SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME

The invention relates to substituted arylpyrazolopyridines according to the general formula (I) : in which A, B, D, E, Ra, R1, R2, R3, R4, R5 and q are as defined in the claims, and salts t

Deamination Reactions, 45. Decomposition of 1-Arylcyclopropanediazonium Ions

1-Arylcyclopropanediazonium ions have been generated by alkaline cleavage of the analogous nitrosocarbamates in methanol.With increasing ?-donor capacity of the aryl groups, retention of the three-membered ring was enhanced while the stereoselectivity (as probed with the aid of 2-D labels) was diminished or entirely lost (4-methoxyphenyl).Where applicable, the stereoselectivity of ring opening is inferior to that of nucleophilic displacement.The data may be interpreted in terms of competing reactions (ks, kc, kΔ) of the cyclopropanediazonium ions.